Compare Quest Diagnostics Inc (DGX) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Newegg Commerce Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Newegg Commerce Inc trades at $11.7 (market cap $243.30M). The key difference: Quest Diagnostics Inc is far larger — about 104.7× Newegg Commerce Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Newegg Commerce Inc for 14 Days on average.
| DGX | NEGG | |
|---|---|---|
Market Cap | $25.48B | $243.30M |
Volume | 941,866 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $92.74 |
52-Week Low | $173.49 | $11.49 |
Typical Hold Time | 56 Days | 14 Days |
Enterprise Value | $31.23B | $213.53M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
NEGG trades at $11.58, down 3.58% today, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 projections. Recent partnerships with Western Digital and HPE highlight strategic moves in AI and enterprise IT markets, while insider selling has created near-term pressure.
The stock presents a mixed picture with improving profitability but significant execution risks. While analyst consensus remains bullish with 100% buy ratings, the $7.75 price target suggests 33% downside from current levels. Key risks include volatile cash flows, competitive e-commerce pressures, and the need to sustain recent margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
